CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Chardan Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
October 28, 2019 10:25 AM EDTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $72.50 price target on CRISPR Therapeutics (NASDAQ: CRSP) after the comapny announced 3Q19 results and provided updates on clinical programs, with dosing initiated in the phase I/II trial (NCT04035434) of allogeneic CAR-T CTX110 in CD19+ cancers, and the follow-on asset, CTX120, targeting BCMA set to... More
